Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Pharmaceuticals, a subsidiary of Mylan Inc, has introduced Letrozole tablets USP, 2.5mg, the generic version of Novartis' Femara tablets, indicated as an adjuvant treatment for postmenopausal women with hormone receptor-positive early stage breast cancer.
Subscribe to our email newsletter
Femara lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.
The launch of the drug follows the settlement and licensing agreement with Novartis.